JP2024525916A5 - - Google Patents

Info

Publication number
JP2024525916A5
JP2024525916A5 JP2024503724A JP2024503724A JP2024525916A5 JP 2024525916 A5 JP2024525916 A5 JP 2024525916A5 JP 2024503724 A JP2024503724 A JP 2024503724A JP 2024503724 A JP2024503724 A JP 2024503724A JP 2024525916 A5 JP2024525916 A5 JP 2024525916A5
Authority
JP
Japan
Prior art keywords
cll
cancer
antibody
seq
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024503724A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525916A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/056676 external-priority patent/WO2023002390A1/en
Publication of JP2024525916A publication Critical patent/JP2024525916A/ja
Publication of JP2024525916A5 publication Critical patent/JP2024525916A5/ja
Pending legal-status Critical Current

Links

JP2024503724A 2021-07-20 2022-07-20 抗cll-1抗体及びその用途 Pending JP2024525916A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20210095142 2021-07-20
KR10-2021-0095142 2021-07-20
KR20210176638 2021-12-10
KR10-2021-0176638 2021-12-10
PCT/IB2022/056676 WO2023002390A1 (en) 2021-07-20 2022-07-20 Anti-cll-1 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024525916A JP2024525916A (ja) 2024-07-12
JP2024525916A5 true JP2024525916A5 (enExample) 2025-07-22

Family

ID=84979134

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024503724A Pending JP2024525916A (ja) 2021-07-20 2022-07-20 抗cll-1抗体及びその用途

Country Status (5)

Country Link
US (1) US20250084158A1 (enExample)
EP (1) EP4373856A4 (enExample)
JP (1) JP2024525916A (enExample)
KR (1) KR20240035504A (enExample)
WO (2) WO2023002390A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4680647A2 (en) * 2023-03-17 2026-01-21 Memorial Sloan-Kettering Cancer Center Antibodies targeting cd3 and uses thereof
CN117964760B (zh) * 2023-12-21 2024-09-03 四川大学华西医院 抗人cll1/cd3的双特异性抗体及其应用
GB202411940D0 (en) * 2024-08-13 2024-09-25 Univ Exeter Anti-CLEC12A Antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE042040T2 (hu) * 2012-09-27 2019-06-28 Merus Nv Bispecifikus IGG antitestek mint T-sejt kapcsolók
US10501545B2 (en) * 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
US9914777B2 (en) * 2015-07-10 2018-03-13 Merus N.V. Human CD3 binding antibody
MX2020007338A (es) * 2018-01-09 2020-11-06 H Lee Moffitt Cancer Ct & Res Composiciones y métodos para el direccionamiento a tipos de cáncer que expresan clec12a.
CN111116753A (zh) * 2018-10-30 2020-05-08 上海泰因生物技术有限公司 一种双特异性抗体的制备方法
US11873338B2 (en) * 2018-12-20 2024-01-16 Merus N.V. CLEC12AxCD3 bispecific antibodies and methods for the treatment of disease
AU2020346886A1 (en) * 2019-09-13 2022-04-14 Memorial Hospital For Cancer And Allied Diseases Anti-CD371 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2023522229A5 (enExample)
IL302078A (en) Anti-CCR8 monoclonal antibodies and their uses
JP2024525916A5 (enExample)
JP2020152735A5 (enExample)
JP2022075818A5 (enExample)
JP2021534096A5 (enExample)
JP2017186337A5 (enExample)
JP2020501531A5 (enExample)
JP2017529838A5 (enExample)
JP2016536020A5 (enExample)
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
JP2017535257A5 (enExample)
JP2017500028A5 (enExample)
JP2022512642A5 (enExample)
JP2017522871A5 (enExample)
RU2018124319A (ru) Новые антитела к клаудину и способы их применения
JP2023518153A5 (enExample)
JP2008537673A5 (enExample)
JP2022527173A5 (enExample)
JP2024534265A5 (enExample)
JP2024538669A5 (enExample)
JP2025507817A5 (enExample)
JP2022526841A5 (enExample)
JP2023549316A5 (enExample)
JP2023517754A5 (enExample)